Strong Buys

Analysts Are Bullish On These 2 Biotech Stocks

“2020 will be remembered as the year of the biotech sector,” declares the author of today’s article, who proceeds to highlight two biotech stocks that Morgan Stanley is bullish on – and which have also earned “Strong Buy” consensus ratings from the analyst community at large. For these two biotech stocks with significant upside potential, CLICK HERE.

These 2 Small-Cap Biotech And Pharma Stocks Boast “Strong Buy” Ratings And Significant Upside Potential

Today’s article highlights two “compelling small-cap stocks that combine a low cost of entry with the Street’s backing.” More specifically, these two stocks – a biotech firm and a pharmaceutical company – are currently trading for less than $8 a share, have earned “Strong Buy” consensus analyst ratings, and boast significant upside potential. For more, CLICK HERE.

3 Compelling Picks From “The Ultimate Risk/Reward Plays”

“With some investors now looking to take on a bit more risk, they are turning to the ultimate risk/reward plays: biotech stocks,” notes the author of today’s article. One of the few major catalysts for biotech stocks is regulatory approval – and the author highlights “three compelling biotech stocks with upcoming Prescription Drug User Fee Act (PDUFA) dates, the deadline…